Clinical trials: Respiratory Syncytial Virus Infections, open to volunteers
- Condition Respiratory Syncytial Virus Infections
- Status Open to volunteers
- Accepts healthy volunteers yes
Respiratory Syncytial Virus Infections
A Study of BLB-201 RSV Vaccine in Infants and Children
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10^6 PFU and 10^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type…
- Trial name
- NCT05655182
- Testing
- PIV5-vectored RSV Vaccine (BLB-201) Low Dose, PIV5-vectored RSV Vaccine (BLB-201) High Dose
- Where
- 18 sites in United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Blue Lake Biotechnology Inc.
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T…
- Trial name
- NCT07618325
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Respiratory Syncytial Virus, Human Metapneumovirus
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
Study VCA25397 is a Phase 2b, observer-blind, randomized, placebo-controlled, parallel, case-driven proof of concept study that will enroll approximately 8000 adults aged 60 years and older to assess the clinical efficacy…
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
- Trial name
- NCT07810010
- Testing
- Bivalent RSV+HMPV protein vaccine
- Where
- 21 sites in Australia, United Kingdom
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention
rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older
This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years.
- Trial name
- NCT07762014
- Testing
- Vaccination with rBCG-N-RSV, Vaccination with conventional BCG (BCG-WT)
- Where
- Greece
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Biothervax SpA
Respiratory Syncytial Virus (RSV)
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of RSVpreF in children 5 to <18 years of age at high risk for RSV disease, including those who are immunocompromised.
- Trial name
- NCT07839871
- Testing
- RSVpreF
- Where
- 20 sites in United States, Japan and 2 more
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Pfizer
Adult, Healthy Participants
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults
The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults. Participants will take part in this study for about 6 months.
- Trial name
- NCT07819097
- Testing
- RSVpreF
- Where
- 15 sites in United States, China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
Respiratory Syncytial Virus Infections
Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.
The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the…
- Trial name
- NCT07582796
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine(CHO cell)(Adjuvanted), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Single adjuvant), Recombinant Respiratory Syncytial Virus Vaccine(CHO cell) (Blank adjuvant)
- Where
- China
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Ab&B Bio-tech Co., Ltd.JS
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older.
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Trial name
- NCT07734649
- Testing
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4
- Where
- 50 sites in United States
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Respiratory Syncytial Virus Infections+Metapneumovirus
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
- Trial name
- NCT07628049
- Testing
- RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine
- Where
- 5 sites in United States, Australia
- Volunteers
- 1,456 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
RSV Immunization
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months.
- Trial name
- PIPELINE-RSV-F (NCT07232706)
- Testing
- Nirsevimab, Abrysvo
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Annecy Genevois
Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection
A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
This is a randomized, observer-blinded, placebo-controlled Phase III clinical trial to evaluate efficacy, immunogenicity and safety of the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in participants aged 60 years and older.
- Conditions
- Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine
- Trial name
- NCT07908654
- Testing
- LYB005
- Where
- China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV)
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults
The main objective of this trial is to evaluate the safety, reactogenicity, and immunogenicity of study interventions across intervention groups
- Trial name
- NCT07764237
- Testing
- mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3)
- Where
- 10 sites in Canada, United Kingdom
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Syncytial Virus (RSV), Respiratory Infection Virus
THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness
RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in…
- Trial name
- THRIVE (NCT07578298)
- Testing
- Nirsevimab (RSV-specific monoclonal antibody)
- Where
- Australia
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
RSV Infections, RSV Immunisation
A Clinical Trial on Safety in Pregnant Women and How Well the Infant is Protected Against RSV-associated Lower Respiratory Tract Infection When the Pregnant Woman Receives the Approved RSV Vaccine Compared to a Placebo.
Respiratory syncytial virus (RSV) is a virus that often affects children during childhood. Even though most cases of RSV are mild, it can cause serious disease and even death - especially in very young babies, babies born too…
- Conditions
- RSV Infections, RSV Immunisation, Preterm Labour
- Trial name
- NCT06955728
- Testing
- Vaccine
- Where
- 11 sites in Ghana, Kenya and 2 more
- Volunteers
- 13,000 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
Respiratory Syncytial Virus (RSV)
RSV Vaccine Pregnancy Registry
The research question is: What is the risk of adverse pregnancy outcomes, including preterm birth, hypertensive disorders, and other maternal and neonatal/infant outcomes, following exposure to RSV vaccine between 32 weeks, 0…
- Trial name
- RSV-PR (NCT06521944)
- Testing
- RSV Vaccine, Non-exposure to RSV Vaccine
- Where
- United States
- Volunteers
- 2,062 people, healthy volunteers welcome
- Sponsor
- CorEvitas
Respiratory Syncytial Virus (RSV)
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell)…
- Trial name
- NCT07272434
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Where
- 8 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Respiratory Syncytial Virus (RSV)
A Clinical Trial of SIBP-A16 Injection in Healthy Adults
This study is a randomized, double-blind, placebo/positive control Phase Ia clinical trial evaluating the safety, tolerability, and pharmacokinetics of SIBP-A16 injection in healthy adults
- Trial name
- NCT07106918
- Testing
- SIBP-A16 injection, Nirsevimab, SIBP-A16 buffer solution
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products